Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

  • Technology appraisal guidance
  • TA897
  • Published: 
Download guidance (PDF)

2 Information about daratumumab with bortezomib and dexamethasone

Marketing authorisation indication

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for daratumumab.

Price

2.3 The list prices for daratumumab (excluding VAT; BNF online, accessed February 2023) are:

  • £4,320 per 1,800 mg/15 ml solution for injection vial

  • £360 per 100 mg/5 ml concentrate for solution for infusion vial

  • £1,440 per 400 mg/20 ml concentrate for solution for infusion vial.

2.4 The company has a commercial arrangement. This makes daratumumab with bortezomib and dexamethasone available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.